Almirall Prodesfarma, S.A.
General Mitre, 151
18 articles with Almirall Prodesfarma, S.A.
Almirall, S.A., the global biopharmaceutical company based in Barcelona, has announced its H1 2021 financial results.
Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year)
Almirall appointed Gianfranco Nazzi as the new CEO, effective May 1, 2021. Mr. Nazzi will bring continuity to the strategy as the business prepares for important launches to support future growth prospects
Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis
Almirall S.A., a global biopharmaceutical company and MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis.
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
AlmirallShare, the open innovation platform of Almirall, S.A., announces two new collaborations with the University of South Australia and the Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau to find new pathways for the treatment of skin cancer and atopic dermatitis.
Almirall, S.A. the global biopharmaceutical company based in Barcelona, has announced that Pablo Alvarez has been promoted and will become the new President & GM of Almirall US, reporting directly to the CEO and serving on the Management Board effective immediately.
Almirall, S.A. the global biopharmaceutical company based in Barcelona, has announced the nomination of Carlos Gallardo as Vice President of the Board of Directors effective immediately.
Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced its 9M 2020 financial results.
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
WuXi Biologics announced the signing of a strategic collaboration agreement enabling Almirall to leverage the proprietary WuXiBody™ platform to develop bispecific antibodies for dermatological diseases.
Spain's leading pharmaceutical company drives seamless customer engagement across multiple stakeholders using face-to-face, email, and web
The deal comes as Dermira plans to initiate Phase III studies in the U.S.
Almirall Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
Results from Phase III pivotal studies to be featured at Late-Breaking Research Program on March 2, 2019
Almirall Prodesfarma and Proteros biostructures GmbH Announce Successful Achievement of Key Scientific Milestone in Structural Biology Collaboration
Forest Laboratories, Inc. and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Forest Laboratories, Inc. And Almirall Announce A Development And Marketing Collaboration Agreement On New Therapy For COPD